Abstract: Dry powder formulations (preferably configured for use with a dry powder inhaler) including a first sub-formulation that includes a first drug and a second sub-formulation that includes a second drug, the first sub-formulation and the second sub-formulation being in physical contact.

Abstract: A composition comprising a solution comprising an active pharmaceutical ingredient comprising an anticholinergic agent, such as ipratropium bromide, and a propellant comprising HFA-152a, HFO-1234ze(E), or both. A metered dose inhaler comprising a metering valve a canister; and an actuator comprising an actuator nozzle; wherein the canister comprises said composition.

Abstract: A metered dose inhaler comprising a metering valve, a canister, an actuator comprising an actuator nozzle, wherein the canister comprises a formulation, the formulation comprising greater than 70% by weight of propellant HFO-1234ze(E), and at least one active pharmaceutical ingredient dissolved in the formulation to form a solution, said active pharmaceutical ingredient preferably selected from beclomethasone, formoterol or tiotropium.

Abstract: In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase.

Abstract: In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase.